1. Medtech Insight
  2. >>Digital Technologies

Coming Together On Pre-Cert: Digital Health World Engages With FDA To Hash Out Regulatory Future

US FDA, industry and other digital health stakeholders huddled at the National Institutes of Health for two days of deep discussions around how the Pre-Certification Pilot was advancing, and how the agency should implement a program that emphasizes certifying "excellence" in company processes. Check out coverage of the meeting and Medtech Insight's exclusive podcast interview with FDA project lead Bakul Patel.

hands in
Pear Therapeutics' David Amor and FDA's Marisa Cruz lead a team huddle after a breakout session at FDA's Pre-Cert workshop. • Source: Ferdous Al-Faruque

Over the past few months, US FDA representatives have made a series of site visits to companies, looking to unearth in-depth details of how the firms operate. But, by all accounts, the atmosphere of the visits wasn't adversarial or tense; it was collaborative.

The reason? The visits were not inspections but company-hosted fact-finding missions, designed to help the agency formulate a regulatory approach centered around evaluating a company's design and development processes more so than product-by-product reviews

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Digital Technologies

Synchron And Apple Team Up To Use ‘Mind-Thought Connection’ To Control iPhones, iPads

 
• By Marion Webb

Apple and Synchron are teaming up to develop technologies that will one day allow people who can’t use their hands or voice to control iPhones, iPads and other Apple devices by using only their thoughts.

Ketryx Wants Its Validated AI Agents To Accelerate Compliance Workflows

 
• By Shubham Singh

While the initial focus is medical devices and life sciences, Ketryx sees future opportunities in other high-regulation sectors including automotive, aerospace and defense, pharma manufacturing and nuclear systems.

Axoft Starts Commercializing Soft BCI-Enabling Materials For R&D Use, Aims To Rewrite BCI Playbook

 
• By Marion Webb

After publishing encouraging results from first-in-human trials of its brain-computer interface, Axoft announced plans to sell its BCI-enabling material Fleuron to researchers and private organizations for R&D use. The company sees this as a revenue stream and feedback loop to refine its BCI platform designed for safer, longer-lasting brain implants.

‘Pathologists Are Hungry For AI-Enabled Digital Pathology’

 
• By Natasha Barrow

Digital pathology makes it possible to unlock insights previously hidden to the human eye, “reshaping how we diagnose and treat patients,” said Nathan Buchbinder, co-founder and chief strategy officer at Proscia. He shared his views on the future of digital pathology and the lessons he has learned from working with pathologists.

More from Medtech Insight

Abbott’s FreeStyle Libre CGM Reduces Cardiovascular Disease-Related Hospitalization

 
• By Natasha Barrow

The REFLECT studies showed a 78% reduction in cardiovascular disease-related hospitalization for people living with type 1 diabetes with prior low blood sugar episodes.

A Deregulated Medtech Sector Could Flourish In Merz’s Industry-Friendly Germany

 
• By Ashley Yeo

Less bureaucracy, no more national supply chain law, framework agreements and competition for direct reimbursement of medtech innovations are among the positive changes the local medtech industry might expect as Germany’s new government gets down to work. Life sciences lawyer Gunnar Sachs offers a view from the ground.

Danaher Faces $350M Tariff Hit, But Says It’s Ready To Absorb The Blow

 
• By Shubham Singh

Despite Danaher’s confident outlook, the company acknowledged near-term profitability fluctuations, particularly in the second quarter. Matt McGrew, Danaher’s CFO, clarified during the company’s first-quarter earnings call on 22 April, that expected operating margin softness in the second quarter – forecast at 25.5% – was not related to tariffs, but to seasonal dynamics in its respiratory diagnostics business.